№ lp_2_1_22474
File format: docx Character count: 50450 File size: 116 KB
Year: 2024
Region / city: Australia
Document Type: Medical Submission
Organization / Institution: PBAC
Author: Not specified
Target audience: Medical practitioners, pharmaceutical authorities
Period of validity: Not specified
Approval date: Not specified
Amendment date: November 2024
Note: Context
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
LEVODOPA WITH CARBIDOPA AND ENTACAPONE, Intestinal gel containing levodopa 20 mg with carbidopa monohydrate 5 mg and with entacapone 20 mg per mL, 47 mL, Lecigon®, STADA PHARMACEUTICALS AUSTRALIA PTY LIMITED
Year: 2023
Region / city: Australia
Document type: Submission for drug listing
Institution: TGA (Therapeutic Goods Administration)
Author: STADA Pharmaceuticals Australia Pty Ltd
Target audience: Medical practitioners, healthcare professionals, policymakers
Period of validity: Not specified
Approval date: August 29, 2023
Date of amendments: Not specified
Clinical claim: LECIG is non-inferior in terms of efficacy and safety compared to LCIG
Registration status: TGA registered
LEVODOPA WITH CARBIDOPA AND ENTACAPONE, Intestinal gel containing levodopa 20 mg with carbidopa monohydrate 5 mg and with entacapone 20 mg per mL, 47 mL, Lecigon®, STADA PHARMACEUTICALS AUSTRALIA PTY LIMITED
Year: 2023
Region / city: Australia
Document type: Submission for drug listing
Institution: TGA (Therapeutic Goods Administration)
Author: STADA Pharmaceuticals Australia Pty Ltd
Target audience: Medical practitioners, healthcare professionals, policymakers
Period of validity: Not specified
Approval date: August 29, 2023
Date of amendments: Not specified
Clinical claim: LECIG is non-inferior in terms of efficacy and safety compared to LCIG
Registration status: TGA registered
LEVODOPA WITH CARBIDOPA: Request for changes to PBS listings for Duodopa®
Year: 2023
Region / City: Australia
Topic: Pharmaceutical listings
Document type: Medical submission
Organization / Institution: AbbVie Pty Ltd
Author: AbbVie Pty Ltd
Target audience: Healthcare professionals, policy makers
Period of validity: Ongoing
Approval date: Not specified
Date of amendments: Not specified
LEVODOPA WITH CARBIDOPA AND ENTACAPONE, Intestinal gel containing levodopa 20 mg with carbidopa monohydrate 5 mg and with entacapone 20 mg per mL, 47 mL, Lecigon®, STADA PHARMACEUTICALS AUSTRALIA PTY LIMITED
Year: 2023
Region / city: Australia
Document type: Submission for drug listing
Institution: TGA (Therapeutic Goods Administration)
Author: STADA Pharmaceuticals Australia Pty Ltd
Target audience: Medical practitioners, healthcare professionals, policymakers
Period of validity: Not specified
Approval date: August 29, 2023
Date of amendments: Not specified
Clinical claim: LECIG is non-inferior in terms of efficacy and safety compared to LCIG
Registration status: TGA registered
LEVODOPA WITH CARBIDOPA: Request for changes to PBS listings for Duodopa®
Year: 2023
Region / City: Australia
Topic: Pharmaceutical listings
Document type: Medical submission
Organization / Institution: AbbVie Pty Ltd
Author: AbbVie Pty Ltd
Target audience: Healthcare professionals, policy makers
Period of validity: Ongoing
Approval date: Not specified
Date of amendments: Not specified
Topics: Entacapone Levodopa Carbidopa